Treatment of Amenorrhea (absence of monthly menstrual periods) with Unani medicine Qurs-e-Foh and Hab-e-Mudir.

Comparative Clinical validation study to assess the safety and efficacy of Unani pharmacopoeial formulation Qurs-e-Foh vs Hab e Mudir in Ehtebas-e-Tams (Amenorrhea) - NILL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097749

Enrollment

110

Registered

2025-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N911- Secondary amenorrhea

Interventions

Intervention1: Qurs-e-Foh : 2 Tab(500mg each) thrice Daily, after meals with water for 5 days. Control Intervention1: Hab e mudir: 2 Tab (500mg each) thrice Daily, after meals with water for 5 days.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients complaining of absence of menstruation for last 3 or more months. 2. Patients with secondary amenorrhoea.

Exclusion criteria

Exclusion criteria: 1. Patients with primary amenorrhea and primary ovarian failure 2. Patients with thyroid dysfunction, PCOD, hyperprolactinaemia 3. Patients with any systemic illness and malignancy 4. Pregnant and lactating woman 5. Patients with bleeding disorders 6. Patients taking Oral Contraceptive Pills(OCPs) /Intra- Uterine contraceptive devices (IUCDs)

Design outcomes

Primary

Measure	Time frame
The safety and efficacy of Unani Pharmacopeial formulation Qurs-e-Foh in comparison with Hab e Mudir in Ehtabas-e-Tams (Amenorrhea) will be carried out on the basis of PBAC (Pictorial blood loss assessment chart) score.Timepoint: At baseline, at the 1st follow-up (1st menstrual cycle), at the 2nd follow-up (2nd menstrual cycle), and at the 3rd follow-up (3rd menstrual cycle), i.e., 0 and three consecutive menstrual cycles. (The patient is advised to report 5 days prior to the expected date of the menstrual period)	—

Measure

Time frame

The safety and efficacy of Unani Pharmacopeial formulation Qurs-e-Foh in comparison with Hab e Mudir in Ehtabas-e-Tams (Amenorrhea) will be carried out on the basis of PBAC (Pictorial blood loss assessment chart) score.Timepoint: At baseline, at the 1st follow-up (1st menstrual cycle), at the 2nd follow-up (2nd menstrual cycle), and at the 3rd follow-up (3rd menstrual cycle), i.e., 0 and three consecutive menstrual cycles. (The patient is advised to report 5 days prior to the expected date of the menstrual period)

—

Secondary

Measure	Time frame
Haematological and biochemical investigations for safety assessment i.e., Hemogram, LFT,KFT, Urine Examination: Routine & Microscopic. Timepoint: At baseline and at the end of treatment. i.e., 0 and 3rd menstrual cycle	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

javed.ghazal@gmail.com09811810454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026